Plant Families & their TherapeuticsPreview
Open in TheBrain

Mitraphylline

Overview

Mitraphylline is a pentacyclic oxindole alkaloid found primarily in Uncaria tomentosa (cat’s claw) and reported in Mitragyna speciosa (kratom). It is non-narcotic and should not be equated with opioid analgesics or with the pharmacology of kratom’s principal alkaloids. The evidence summarized here is largely preclinical; clinical efficacy and safety for treating disease remain insufficiently established.

Chemical profile

Reported biological activities

Anti-inflammatory activity

Mitraphylline has been reported to modulate inflammatory responses in cellular and experimental models. Proposed effects include reducing the release or expression of pro-inflammatory mediators and cytokines, including IL-1α, IL-1β, IL-4, IL-17, and TNF-α. These findings may help explain interest in U. tomentosa constituents for inflammatory conditions, but they do not establish that isolated mitraphylline treats arthritis, cardiovascular disease, cancer, or other human illnesses.

Antiproliferative and cytotoxic activity

Laboratory studies have described cytotoxic or antiproliferative effects against selected human cancer cell lines, including Ewing’s sarcoma, breast cancer, glioma, and neuroblastoma models. Such findings are hypothesis-generating only: activity in cultured cells does not demonstrate effectiveness in patients, an appropriate dose, selectivity for tumor cells, or clinical safety.

Therapeutic context and limitations

Mitraphylline has been investigated as one constituent of Uncaria tomentosa, traditionally used in preparations associated with inflammatory complaints. However:

Tissue-State Relevance

Overall tissue-state impression:

Strongest relationship: Heat / Excitation ↓

Secondary: Wind / Tension ↓

Possible Damp / Stagnation ↓

Little basis for assigning it strongly to Cold, Dry, or Damp / Relaxation.

Mechanisms

Experimental work demonstrates an anti-inflammatory immunomodulatory action, including suppression of inflammatory cytokine production. In a mouse LPS model, oral mitraphylline reduced IL-1α, IL-1β, IL-17 and TNF-α release by roughly 50%, with an additional reduction in IL-4.

In human primary neutrophils, mitraphylline reduced LPS-induced activation and reduced expression/secretion of TNF-α, IL-6 and IL-8.

There is also evidence that mitraphylline changes monocyte/macrophage differentiation toward an M2-like phenotype, suggesting that its action isn't simply nonspecific immune suppression but may involve changing the character of inflammatory immune responses.

A separate in-vitro study found neuroprotective effects and inhibition of amyloid aggregation, but this is considerably farther from clinical evidence.

Tissue-state interpretation

Heat / Excitation — strongly reducing

This is the cleanest mapping.

If we translate Heat/Excitation into physiological language—excess inflammatory signaling, heightened immune activity, tissue irritation and excessive cellular activation—mitraphylline has several mechanisms that point toward reducing that state.

The important nuance is that it doesn't necessarily mean "cooling" in a literal thermodynamic sense. It is better understood as down-regulating excessive inflammatory excitation.

Wind / Tension — potentially reducing

This is a more indirect association.

If inflammatory signaling contributes to pain, neural irritation and tissue reactivity, reducing TNF-α/IL-6/IL-8 and inflammatory-cell activation could reduce the inflammatory component of a Wind/Tension presentation.

But I would not classify mitraphylline as a primary antispasmodic POA based on current evidence.

Damp / Stagnation — potentially reducing

Again, indirectly.

Inflammatory congestion involves accumulation of activated immune cells and inflammatory mediators. Mitraphylline's effects on neutrophil activation and inflammatory cytokines could theoretically reduce this component of stagnation.

But there isn't sufficient evidence to say that mitraphylline directly improves lymphatic, venous or interstitial fluid movement.

Cold / Depression — neutral to potentially aggravating in a theoretical framework

There isn't convincing evidence that mitraphylline is strongly stimulating tissue function. Therefore, I would be cautious about calling it appropriate for a Cold/Depression state.

Damp / Relaxation — relatively neutral

There isn't a strong demonstrated effect on tissue tone or laxity.

Dry / Atrophy — relatively neutral

Anti-inflammatory action shouldn't automatically be interpreted as nourishing or moistening. In fact, in a profoundly depleted Dry/Atrophy pattern, suppressing inflammatory signaling isn't necessarily the primary therapeutic direction.

Clinical-pattern relevance

The strongest clinical-pattern translation is:

Inflammatory/immune-excess pattern → excessive cytokine/neutrophil activity → mitraphylline-mediated attenuation

That makes mitraphylline particularly interesting where the clinical picture resembles inflammatory Heat, especially when inflammatory activation is prominent.

There is human evidence for the pentacyclic chemotype extract in rheumatoid arthritis, but this cannot be attributed specifically to mitraphylline. In a small randomized trial, the extract produced a greater reduction in painful joints than placebo over 24 weeks, with only minor side effects reported.

Safety note

The safety database for isolated mitraphylline is much thinner than that for U. tomentosa preparations.

One animal/in-vitro study found no toxicity to tested cell lines or macrophages up to 100 μM under those experimental conditions.

For clinical safety, however, the more relevant evidence concerns Uncaria preparations. NCCIH notes potential interactions with anticoagulant/antiplatelet drugs, antihypertensives, calcium-channel blockers, CYP3A4 substrates and immunosuppressants.

So I would not extrapolate "mitraphylline appears non-toxic in this experiment" into "isolated mitraphylline is clinically established as safe."

Do not use this information as a substitute for medical care. Concentrated alkaloid products may interact with medicines or be unsuitable in pregnancy, autoimmune disease, liver or kidney disease, or before surgery. Anyone considering a mitraphylline- or cat’s-claw-containing product should discuss it with a qualified clinician or pharmacist, especially when taking immunomodulators, anticoagulants, antihypertensives, or other prescription medicines.

Articles / studies

The following references from the original note have been retained:

Research questions

Attachments